KATLYN NORTON: Open Payments
NPI 1770165672 · VERNON, AL. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$490 in 30 payments from 8 companies in 2025. Trend: 2023 $99 · 2024 $264 · 2025 $490
Food & beverage: $490
| Company | Payments | Amount |
|---|---|---|
| Otsuka America Pharmaceutical, Inc. | 20 | $317 |
| Amgen Inc. | 2 | $41 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 2 | $33 |
| Xeris Pharmaceuticals, Inc. | 2 | $32 |
| ABBVIE INC. | 1 | $20 |
| AstraZeneca Pharmaceuticals LP | 1 | $18 |
| Novo Nordisk Inc | 1 | $16 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 1 | $14 |
Products named: REXULTI, REPATHA, CAPLYTA, GVOKE HYPOPEN, QULIPTA, Wegovy, XIFAXAN.
Industry payments across AL — which companies pay providers there.
